hirudin and Neoplasms

hirudin has been researched along with Neoplasms* in 7 studies

Other Studies

7 other study(ies) available for hirudin and Neoplasms

ArticleYear
Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis.
    Cancer research, 2008, Jun-15, Volume: 68, Issue:12

    Cathepsin D (CD) up-regulation has been associated with human malignancy and poor prognosis. Thrombin up-regulated CD mRNA and protein in eight tumor cell lines as well as in human umbilical vascular endothelial cells (HUVEC). Thrombin increased the secretion of CD by 3- to 8-fold and enhanced chemotaxis ( approximately 2-fold) in 4T1 murine mammary CA cells, which was completely inhibited with the knockdown of CD. Secreted 4T1 CD induced neoangiogenesis by 2.4-fold on a chick chorioallantoic membrane, which was blocked in CD-KD cells. The addition of pure CD (2 ng) to the chick chorioallantoic membrane increased angiogenesis by 2.1-fold, which was completely inhibited by Pepstatin A (Pep A). CD enhanced human HUVEC chemotaxis and Matrigel tube formation by 2-fold, which was then blocked by Pep A. CD enhanced HUVEC matrix metalloproteinase 9 (MMP-9) activity by approximately 2-fold, which was completely inhibited by Pep A as well as a generic MMP inhibitor, GM6001. The injection of CD-KD 4T1 cells into syngeneic mice inhibited tumor growth by 3- to 4-fold compared with empty vector (EV) cells. Hirudin, a specific thrombin inhibitor, inhibited the growth of wild-type and EV cells by 2- to 3-fold, compatible with thrombin up-regulation of CD. CD and thrombin also contributed to spontaneous pulmonary metastasis; 4-fold nodule inhibition with CD versus EV and 4.6-fold inhibition with hirudin versus EV (P < 0.02). Thus, thrombin-induced CD contributes to the malignant phenotype by inducing tumor cell migration, nodule growth, metastasis, and angiogenesis. CD-induced angiogenesis requires the proteolytic activation of MMP-9.

    Topics: Animals; Blotting, Western; Cathepsin D; Cell Movement; Cells, Cultured; Chemotaxis; Chick Embryo; Chorioallantoic Membrane; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Hirudins; Humans; Immunoprecipitation; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Neoplasms; Neovascularization, Pathologic; Pepstatins; RNA, Messenger; RNA, Small Interfering; Thrombin; Umbilical Veins; Up-Regulation

2008
[Thrombin induced tumour growth - pharmacological control].
    Hamostaseologie, 2007, Volume: 27, Issue:2

    The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

    Topics: Amino Acid Sequence; Cell Division; Hirudins; Humans; Models, Molecular; Molecular Sequence Data; Neoplasms; Protein Conformation; Receptor, PAR-1; Receptors, Thrombin; Signal Transduction; Thrombin

2007
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation.
    Cancer research, 2004, Dec-01, Volume: 64, Issue:23

    Coagulation has long been known to facilitate metastasis. To pinpoint the steps where coagulation might play a role in the metastasis, we used three-dimensional visualization of direct infusion of fluorescence labeled antibody to observe the interaction of tumor cells with platelets and fibrinogen in isolated lung preparations. Tumor cells arrested in the pulmonary vasculature were associated with a clot composed of both platelets and fibrin(ogen). Initially, the cells attached to the pulmonary vessels were rounded. Over the next 2 to 6 hours, they spread on the vessel surface. The associated clot was lysed coincident with tumor cell spreading. To assess the importance of clot formation, we inhibited coagulation with hirudin, a potent inhibitor of thrombin. The number of tumor cells initially arrested in the lung of hirudin-treated mice was essentially the same as in control mice. However, tumor cell spreading and subsequent retention of the tumor cells in the lung was markedly inhibited in the anticoagulated mice. These associations of the tumor cells with platelets were independent of tumor cell expression of P-selectin ligands. This work identifies tumor cell spreading onto the vascular surface as an important component of the metastatic cascade and implicates coagulation in this process.

    Topics: Adenocarcinoma; Animals; Blood Coagulation; Blood Platelets; Cell Communication; Cell Line, Tumor; Colonic Neoplasms; Fibrinogen; Fibrosarcoma; Hirudins; Humans; Lung; Lung Neoplasms; Melanoma; Melanoma, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Neoplastic Cells, Circulating; Rats; Thrombin

2004
Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.
    In vitro cellular & developmental biology. Animal, 1997, Volume: 33, Issue:3

    Platelets and coagulation are involved in the pathogenesis of blood-borne metastases. The aim of this study is to obtain more information about the mechanisms involved in the initial adhesion of tumor cells to endothelial cells. In short term experiments with tumor cells, suspended in the medium of cultured endothelial cells, we tested whether addition of both platelets and thrombin cause more tumor cell adhesion to endothelial cells, than when either platelets or thrombin are acting alone. HeLa cells or HT29 cells, prelabeled with radioactive 51Cr, human platelets, and thrombin were added to human endothelial cell cultures. Following 15 min of shaking at 37 degrees C, the percentage of tumor cell adhesion was calculated. The percentages of adhering tumor cells with the presence of both platelets and thrombin were greatly increased compared to controls. Addition of hirudin 2 min before thrombin lowered the adhesion percentage of tumor cells. Hirudin added immediately before and 2 min after thrombin gave only minor effects. When the endothelium was treated with superoxide dismutase, catalase, and mannitol, the adhesion of tumor cells was lowered with catalase and superoxide dismutase. The cause of tumor cell-endothelial cell interaction is probably complex. Our results show that activated platelets enhance the tumor cell adhesion, and that generation of active oxygen species may be important in the initial phase of the interaction.

    Topics: Adult; Blood Platelets; Catalase; Cell Adhesion; Endothelium, Vascular; HeLa Cells; Hirudins; Humans; Mannitol; Neoplasms; Superoxide Dismutase; Thrombin; Tumor Cells, Cultured; Umbilical Veins

1997
Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding.
    Thrombosis and haemostasis, 1995, Volume: 73, Issue:5

    Cellular sites of coagulation activation within complex, intact tissues have been studied by immunohistochemical techniques. Hirudin, a specific and high affinity inhibitor of the active site of thrombin, together with antibody to hirudin were applied to sections of AMeX-fixed specimens of normal lung, kidney, placenta, freshly incised skin and unperturbed skin obtained at fresh autopsy; to rheumatoid synovial tissue; and to malignant tissue from a variety of tumor types. Staining for thrombin was observed selectively on pulmonary alveolar, rheumatoid synovial, and placental macrophages that express an intact extrinsic coagulation pathway. Staining was also observed restricted to the endothelium of capillaries in freshly incised skin but not in either unperturbed skin or in aged incisions. Staining of tumor cell bodies was observed in small cell carcinoma of the lung, renal cell carcinoma, and malignant melanoma tissues that we found previously to show tumor cell-associated procoagulant activity. This staining occurred commonly on cells within the tumor mass that were distant from stromal fibrinogen/fibrin. By contrast, tumor-associated macrophage but not tumor cell staining was seen in adenocarcinoma and squamous cell carcinoma of the lung, and little or no staining was seen colon cancer tissue. Negative controls in which either the hirudin probe or its antibody were omitted failed to show staining. These results are in accord with previous findings and suggest that such techniques may be useful for studying the cellular sites of thrombin generation in intact tissues. We postulate that administration of potent and specific thrombin antagonists, such as hirudin, to patients with relevant tumor types might be followed by homing of hirudin to tumor cells in vivo so that effects of local thrombin generation on malignant progression can be determined.

    Topics: Arthritis, Rheumatoid; Blood Coagulation; Endothelium, Vascular; Hirudins; Humans; Immunoenzyme Techniques; Macrophages; Neoplasm Proteins; Neoplasms; Organ Specificity; Placenta; Protein Binding; Skin; Subcellular Fractions; Synovial Fluid; Thrombin; Viscera

1995
Thromboxane production by platelets during tumor cell-induced platelet activation.
    Invasion & metastasis, 1991, Volume: 11, Issue:2

    We have evaluated in a homologous system the mechanisms of platelet activation by cells isolated from fresh human tumor tissues and the role of thromboxane B2 (TxB2) generation in this process. Thirty-eight of the 46 tumor tissues considered showed a high platelet-aggregating activity, with no particular distribution in any specific tumor type. Apyrase caused a nonsignificant reduction in the aggregation response, hirudin did not change it, while iodoacetic acid or p-hydroxymercuriphenylsulfonate, specific cysteine proteinase inhibitors, significantly reduced the platelet-aggregating capacity of these tumor cells. In 9 colon carcinomas and in 8 breast carcinomas the levels of TxB2 produced by platelets after addition of tumor cells were measured: tumor cell-induced platelet aggregation was accompanied by a significant production of the metabolite; indobufen, a cyclooxygenase inhibitor, significantly reduced aggregation and particularly TxB2 production, while the drug had no effect on both parameters if preincubated with tumor cells only. These data suggest that cells isolated from different human tumor tissues activate platelets through the activity of tumor-associated cysteine proteinase(s); platelet aggregation by tumor cells is largely dependent on arachidonic acid metabolism in platelets, while such metabolism in tumor cells does not play a significant role.

    Topics: Adult; Apyrase; Blood Platelets; Dose-Response Relationship, Drug; Hirudins; Humans; Iodoacetates; Iodoacetic Acid; Isoindoles; Neoplasms; Phenylbutyrates; Phenylmercury Compounds; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Radioimmunoassay; Thromboxane B2

1991
Differentiation of platelet-aggregating effects of human tumor cell lines based on inhibition studies with apyrase, hirudin, and phospholipase.
    Cancer research, 1982, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Animals; Apyrase; Cell Line; Colonic Neoplasms; Glioma; Hirudins; Humans; Kinetics; Lung Neoplasms; Melanoma; Mesothelioma; Mice; Neoplasms; Neoplasms, Experimental; Neuroblastoma; Phospholipases; Phosphoric Monoester Hydrolases; Platelet Aggregation

1982